Search review questions

Incidence of (author‐defined) suspected infections within the first 28 days of life · Neonates and caregivers

All‐cause mortality within the first seven days of life (early neonatal death) · Neonates and caregivers

All‐cause mortality from the 8th to 28th day of life (late neonatal death) · Neonates and caregivers

Incidence of bacteriologically confirmed infections within the first 28 days of life · Neonates and caregivers

Failed CPAP · preterm infants with apnoea of prematurity

Adverse events · preterm infants, 24 to 29 weeks gestation and mean age 18 days with apnoea of prematurity

Long‐term neurodevelopmental outcomes · preterm infants, 24 to 29 weeks gestation and mean age 18 days with apnoea of prematurity

Long‐term neurodevelopmental outcomes · preterm infants with apnoea of prematurity (gestation 27 weeks, age not stated)

Mean apnoea events · preterm infants with apnoea of prematurity

Adverse events · preterm infants with apnoea of prematurity

Long‐term neurodevelopmental outcomes · preterm infants with apnoea of prematurity

Long‐term neurodevelopmental outcomes · preterm infants with apnoea of prematurity (median age 9 days)

Failed CPAP · preterm infants, 24 to 29 weeks gestation and mean age 18 days with apnoea of prematurity

Mean apnoea events · preterm infants, 24 to 29 weeks gestation and mean age 18 days with apnoea of prematurity

Overweight · healthy, full‐term (37 to 42 weeks), formula‐fed infants

Obesity · healthy, full‐term (37 to 42 weeks), formula‐fed infants

All‐cause mortality · healthy, full‐term (37 to 42 weeks), formula‐fed infants

All‐cause mortality · healthy, full‐term, formula‐fed infants

Major neurodevelopmental disability · preterm infants at risk for apnea

Major neurodevelopmental disability at 18 to 24 months · preterm infants with apnea

Death at hospital discharge · preterm infants prior to extubation

Major neurodevelopmental disability at 18 to 24 months · preterm infants prior to extubation

All‐cause mortality throughout the hospital admission of the participant · neonates that require central line

The proportion of infants or catheters with exit‐site infection, either microbiologically or clinically documented · neonates that require central line

Premature central line removal, defined as number of central venous catheters (CVCs) removed in the trial as deemed by the author as the source of infection · neonates that require central line

The proportion of infants or catheters with exit‐site infection, either microbiologically or clinically documented · neonates that require central line

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants at risk for apnea of prematurity

Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants at risk for apnea of prematurity

Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of caffeine · preterm infants at risk for apnea of prematurity

Seizures (clinically diagnosed; diagnosed by electroencephalography) · preterm infants at risk for apnea of prematurity

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with or at risk for apnea of prematurity

Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with or at risk for apnea of prematurity

Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity

Duration of hospital stay (days) · preterm infants with or at risk for apnea of prematurity

Seizures (clinically diagnosed; diagnosed by electroencephalography) · preterm infants with or at risk for apnea of prematurity

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with or at risk for apnea of prematurity

Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity

Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity

Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of caffeine · preterm infants with or at risk for apnea of prematurity

Duration of hospital stay (days) · preterm infants with or at risk for apnea of prematurity

Seizures (clinically diagnosed; diagnosed by electroencephalography) · preterm infants with or at risk for apnea of prematurity

Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity

4a.Death at any time during initial hospitalization – doxapram compared to no treatment for the treatment of apnea · treatment of apnea

4b. Death at any time during initial hospitalization – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea

4c. Death at any time during initial hospitalization – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea

5a. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the treatment of apnea · treatment of apnea

5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea

5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea

6c. Side effects causing cessation of therapy – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea